Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

Pan Tang,Jifa Zhang,Jie Liu,Cheng-Ming Chiang,Liang Ouyang
DOI: https://doi.org/10.1021/acs.jmedchem.0c01487
IF: 8.039
2021-02-22
Journal of Medicinal Chemistry
Abstract:Bromodomain and extraterminal (BET) proteins bind acetylated lysine residues in histones and nonhistone proteins via tandem bromodomains and regulate chromatin dynamics, cellular processes, and disease procession. Thus targeting BET proteins is a promising strategy for treating various diseases, especially malignant tumors and chronic inflammation. Many pan-BET small-molecule inhibitors have been described, and some of them are in clinical evaluation. Nevertheless, the limited clinical efficacy of the current BET inhibitors is also evident and has inspired the development of new technologies to improve their clinical outcomes and minimize unwanted side effects. In this Review, we summarize the latest protein characteristics and biological functions of BRD4 as an example of BET proteins, analyze the clinical development status and preclinical resistance mechanisms, and discuss recent advances in BRD4-selective inhibitors, dual-target BET inhibitors, proteolysis targeting chimera degraders, and protein–protein interaction inhibitors.This article has not yet been cited by other publications.
chemistry, medicinal
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to explore drug discovery strategies targeting bromodomain and extra-terminal (BET) proteins, from current progress to technological developments. Specifically, the paper focuses on the following aspects: 1. **Functions and Characteristics of BET Proteins**: - BET proteins regulate chromatin dynamics, cellular processes, and disease progression by binding to acetylated lysine residues on histones and non-histone proteins through their tandem bromodomains. - Special emphasis is placed on BRD4 as an example of BET proteins, summarizing its latest structural and functional characteristics. 2. **Current Status of Clinical Development and Preclinical Resistance Mechanisms**: - Analyzes the current clinical development status of BET inhibitors, including some inhibitors undergoing clinical trials (such as OTX-015, CPI-0610, and I-BET762). - Discusses the issues encountered by these inhibitors in clinical trials, such as toxicity, dose-limiting toxicity, and limited clinical efficacy. - Explores preclinical resistance mechanisms, including the activation of alternative or compensatory pathways (such as WNT/β-catenin and Hedgehog signaling pathways) and increased BRD4 phosphorylation. 3. **Development of Next-Generation Inhibitors**: - Introduces newly developed technologies to facilitate the discovery of more selective inhibitors, such as BD1-selective inhibitors, BD2-selective inhibitors, BRD4-selective inhibitors, dual-target inhibitors, and protein-protein interaction inhibitors. - Emphasizes the potential of these next-generation inhibitors to overcome the limited clinical efficacy and off-target toxicity of existing BET inhibitors. ### Summary The paper mainly focuses on the application of BET proteins in drug discovery, particularly the functions and characteristics of BRD4. By summarizing the current status of clinical development and preclinical resistance mechanisms, the paper highlights the importance of developing more selective and effective next-generation inhibitors to improve therapeutic outcomes and reduce side effects.